ArticleSurgery2012
Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.
Article in Surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03053284 (Pasireotide for Prevention of Hypoglycemia in Patients With Hyperinsulinemic Hypoglycemia), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pasireotide for Prevention of Hypoglycemia in Patients With Hyperinsulinemic Hypoglycemia
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression.The Journal of clinical endocrinology and metabolism · 2023Article
- An Insight on Functioning Pancreatic Neuroendocrine Neoplasms.Biomedicines · 2023Review
- Preclinical Models of Neuroendocrine Neoplasia.Cancers · 2022Review
- Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors.Journal for immunotherapy of cancer · 2022Article
- Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.Oncogenesis · 2021Article
- Review
- Multiple Endocrine Neoplasia Type 1: Latest Insights.Endocrine reviews · 2021Review
- Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.International journal of molecular sciences · 2019Review
- Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).World journal of surgery · 2019Article
- The effect of pasireotide on intestinal anastomotic healing with and without whole-body irradiation in a rat model.International journal of colorectal disease · 2019Article
- Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.Journal of the National Cancer Institute · 2018Article
- Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches.Endocrinology and metabolism clinics of North America · 2018Review
- Current and emerging therapies for PNETs in patients with or without MEN1.Nature reviews. Endocrinology · 2018Review
- The future: genetics advances in MEN1 therapeutic approaches and management strategies.Endocrine-related cancer · 2017Review
- The treatment of hyperinsulinemic hypoglycaemia in adults: an update.Journal of endocrinological investigation · 2017Review
- Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Expert opinion on pharmacotherapy · 2016Review
- Article
- AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours.Nature reviews. Endocrinology · 2013Article
- Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for basic and preclinical studies.International journal of endocrine oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundPasireotide (SOM230), a long-acting somatostatin analogue (LAR), has improved agonist activity at somatostatin receptors. We tested the effect of SOM230 on insulin secretion, serum glucose concentrations, tumor growth, and survival using an MEN1 transgenic mouse model.
methodsEight 12-month-old conditional Men1 knockout mice with insulinoma were assessed. The treatment (n = 4) and control groups (n = 4) received monthly subcutaneous injections of SOM230 or PBS. Serum insulin and glucose levels were determined by enzyme-linked immunosorbent assay and enzymatic colorimetric assay, respectively. Tumor activity, growth, and apoptosis were determined by microPET/CT scan and histologic analysis.
resultsOn day 7, there was a decrease in serum insulin levels from 1.06 ± 0.28 μg/L to 0.37 ± 0.17 μg/L (P = .0128) and a significant increase in serum glucose from 4.2 ± 0.45 mmol/L to 7.12 ± 1.06 mmol/L (P = .0075) in the treatment group but no change in the control group. Tumor size was less in the treatment group (2,098 ± 388 μm(2)) compared with the control group (7,067 ± 955 μm(2); P = .0024). Furthermore, apoptosis was increased in the treatment group (6.9 ± 1.23%) compared with the control group (0.29 ± 0.103%; P = .002).
conclusionSOM230 demonstrates antisecretory, antiproliferative, and proapoptotic activity in our MEN1 model of insulinoma. Further studies of the effects of SOM230 in PNET patients with MEN1 mutations are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.